Published in J Neurochem on April 01, 2010
Middle cerebral artery occlusion model in rodents: methods and potential pitfalls. J Biomed Biotechnol (2011) 1.46
Advanced drug delivery systems for antithrombotic agents. Blood (2013) 0.92
MicroRNAs in cerebral ischemia-induced neurogenesis. J Neuropathol Exp Neurol (2013) 0.89
Perlecan domain V therapy for stroke: a beacon of hope? ACS Chem Neurosci (2012) 0.82
MiR-126 Contributes to Human Umbilical Cord Blood Cell-Induced Neurorestorative Effects After Stroke in Type-2 Diabetic Mice. Stem Cells (2016) 0.82
Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier. Ther Deliv (2015) 0.81
Comparison of surgical methods of transient middle cerebral artery occlusion between rats and mice. J Vet Med Sci (2014) 0.81
Biomedical and clinical promises of human pluripotent stem cells for neurological disorders. Biomed Res Int (2013) 0.80
Targeting nitric oxide in the subacute restorative treatment of ischemic stroke. Expert Opin Investig Drugs (2013) 0.79
Superior Neuroprotective Efficacy of LAU-0901, a Novel Platelet-Activating Factor Antagonist, in Experimental Stroke. Transl Stroke Res (2011) 0.78
Middle cerebral artery occlusion methods in rat versus mouse models of transient focal cerebral ischemic stroke. Neural Regen Res (2014) 0.77
RBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral Photothrombosis. Transl Stroke Res (2012) 0.75
Gastrodia and Uncaria (tianma gouteng) water extract exerts antioxidative and antiapoptotic effects against cerebral ischemia in vitro and in vivo. Chin Med (2016) 0.75
Effects of skilled reach training with affected forelimb and treadmill exercise on the expression of neurotrophic factor following ischemia-induced brain injury in rats. J Phys Ther Sci (2017) 0.75
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med (1995) 47.15
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA (1995) 13.37
Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci (2006) 12.23
Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci (2004) 9.29
Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci (2003) 6.53
Neonatal brain injury. N Engl J Med (2004) 5.40
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
Cerebral sinovenous thrombosis in children. N Engl J Med (2001) 4.81
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med (1998) 4.09
NXY-059 for the treatment of acute ischemic stroke. N Engl J Med (2007) 3.70
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med (2008) 3.64
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest (2003) 3.41
Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab (2003) 3.14
Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature (1995) 3.06
Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol Rev (1998) 2.98
Report of the National Institute of Neurological Disorders and Stroke workshop on perinatal and childhood stroke. Pediatrics (2002) 2.88
Thrombolysis for ischemic stroke in children: data from the nationwide inpatient sample. Stroke (2007) 2.74
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem (1984) 2.22
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol (2003) 2.03
Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci (2008) 1.97
Stroke in newborn infants. Lancet Neurol (2004) 1.94
Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke (2009) 1.90
The later growth of the brain and its vulnerability. Pediatrics (1974) 1.88
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation (2008) 1.84
Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke (2005) 1.77
The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci (2003) 1.71
Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A (2000) 1.66
The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A (2000) 1.65
In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood (2003) 1.53
tPA and proteolysis in the neurovascular unit. Stroke (2004) 1.47
Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci U S A (2005) 1.45
Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Proc Natl Acad Sci U S A (1992) 1.45
Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke (2009) 1.44
Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci (2006) 1.38
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science (1999) 1.37
Protein kinase C and cerebral vasospasm. J Cereb Blood Flow Metab (2001) 1.37
Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis (2008) 1.37
Neuroserpin, an axonally secreted serine protease inhibitor. EMBO J (1996) 1.33
Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke (2001) 1.32
Key role of tissue plasminogen activator in neurovascular coupling. Proc Natl Acad Sci U S A (2008) 1.30
Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke (2009) 1.30
LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol (2006) 1.26
Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem (2002) 1.26
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Brain Res Dev Brain Res (2005) 1.23
Experimental acute subdural hematoma in infant piglets. Pediatr Neurosurg (1996) 1.20
Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Stroke (2001) 1.19
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. J Cereb Blood Flow Metab (2008) 1.18
Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther (2004) 1.16
Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling. J Biol Chem (2004) 1.16
The cost of pediatric stroke acute care in the United States. Stroke (2009) 1.16
Nitric oxide mediates neurodegeneration and breakdown of the blood-brain barrier in tPA-dependent excitotoxic injury in mice. J Cell Sci (2006) 1.14
Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep (2002) 1.13
Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Hum Pathol (1999) 1.12
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood (2006) 1.11
Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke (2005) 1.11
uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res (2008) 1.09
Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice. Neuroreport (1999) 1.06
Symptomatic ischemic stroke in full-term neonates : role of acquired and genetic prothrombotic risk factors. Stroke (2000) 1.05
Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs (2007) 1.03
Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab (2009) 1.02
Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neurosci Lett (2007) 1.01
Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J Cereb Blood Flow Metab (1999) 1.00
Age dependent NMDA contribution to impaired hypotensive cerebral hemodynamics following brain injury. Brain Res Dev Brain Res (2002) 0.98
Role of endothelin-1 in age-dependent cerebrovascular hypotensive responses after brain injury. Am J Physiol (1999) 0.96
Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo. J Pharmacol Exp Ther (2005) 0.94
New pediatric model of ischemic stroke in infant piglets by photothrombosis: acute changes in cerebral blood flow, microvasculature, and early histopathology. Stroke (2007) 0.93
Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury. J Neurotrauma (2009) 0.93
Intra-arterial thrombolysis in a 2-year-old with cardioembolic stroke. J Child Neurol (2007) 0.92
Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats. J Cereb Blood Flow Metab (2007) 0.92
Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the neuroprotection after embolic stroke. Stroke (2008) 0.91
Desmoteplase. Expert Opin Biol Ther (2009) 0.89
Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice. J Cereb Blood Flow Metab (2002) 0.88
Treating acute ischemic stroke. Curr Opin Drug Discov Devel (2008) 0.87
Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs (2001) 0.85
Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rat at 1 and 4 hours after embolic stroke. J Cereb Blood Flow Metab (2000) 0.84
Taming the clot-buster tPA. Nat Med (2006) 0.83
Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia. Am J Physiol Heart Circ Physiol (2009) 0.82
Successful treatment of pediatric stroke with recombinant tissue plasminogen activator (rt-PA): a case report and review of the literature. CJEM (2008) 0.82
NOC/oFQ contributes to age-dependent impairment of NMDA-induced cerebrovasodilation after brain injury. Am J Physiol Heart Circ Physiol (2000) 0.80
Novel thrombolytic drugs: will they make a difference in the treatment of ischaemic stroke? CNS Drugs (2008) 0.79
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol (2002) 4.33
Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain (2013) 3.87
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther (2008) 2.69
Clearance of the cervical spine in clinically unevaluable trauma patients. Spine (Phila Pa 1976) (2010) 2.65
Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet (2004) 2.65
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci (2003) 2.34
Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease? Nat Rev Neurosci (2010) 2.34
Cost-effectiveness of current treatment strategies for lumbar spinal stenosis: nonsurgical care, laminectomy, and X-STOP. J Neurosurg Spine (2010) 2.32
Is aggressive treatment of traumatic brain injury cost-effective? J Neurosurg (2012) 2.22
Axonal pathology in traumatic brain injury. Exp Neurol (2012) 2.20
Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol (2007) 2.15
Widespread τ and amyloid-β pathology many years after a single traumatic brain injury in humans. Brain Pathol (2011) 2.11
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol (2003) 2.03
Utility of delayed surgical repair of neonatal brachial plexus palsy. J Neurosurg Pediatr (2014) 1.97
Anterior surgical management of single-level cervical disc disease: a cost-effectiveness analysis. Spine (Phila Pa 1976) (2014) 1.96
Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther (2006) 1.93
Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost (2003) 1.91
Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res (2012) 1.85
How I treat heparin-induced thrombocytopenia. Blood (2012) 1.85
Structure of human urokinase plasminogen activator in complex with its receptor. Science (2006) 1.84
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation (2008) 1.84
Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol (2005) 1.81
Extreme stretch growth of integrated axons. J Neurosci (2004) 1.76
PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol (2003) 1.74
Nuclear translocation of urokinase-type plasminogen activator. Blood (2008) 1.66
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood (2004) 1.63
Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol (2004) 1.63
Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury. Am J Respir Crit Care Med (2008) 1.62
Amyloid beta accumulation in axons after traumatic brain injury in humans. J Neurosurg (2003) 1.60
Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol (2013) 1.60
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood (2005) 1.59
Dynamic antibody-binding properties in the pathogenesis of HIT. Blood (2012) 1.59
Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis. Addiction (2012) 1.58
ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood (2004) 1.58
Traumatic axonal injury induces proteolytic cleavage of the voltage-gated sodium channels modulated by tetrodotoxin and protease inhibitors. J Neurosci (2004) 1.55
Advanced drug delivery systems that target the vascular endothelium. Mol Interv (2006) 1.54
Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol (2003) 1.54
In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood (2003) 1.53
Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proc Natl Acad Sci U S A (2010) 1.53
Mechanical breaking of microtubules in axons during dynamic stretch injury underlies delayed elasticity, microtubule disassembly, and axon degeneration. FASEB J (2009) 1.52
Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. Blood (2012) 1.50
Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood (2004) 1.50
A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol (2008) 1.46
Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol (2003) 1.46
Durability of Roux-en-Y gastric bypass surgery: a meta-regression study. Ann Surg (2012) 1.44
Decompressive hemicraniectomy for pediatric traumatic brain injury: long-term outcome based on quality of life. Pediatr Neurosurg (2011) 1.44
Geographic variation in outcomes from severe traumatic brain injury. World Neurosurg (2011) 1.44
How large is the typical subarachnoid hemorrhage? A review of current neurosurgical knowledge. World Neurosurg (2011) 1.41
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood (2012) 1.40
Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program (2004) 1.38
Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci (2006) 1.38
Choosing the best operation for chronic subdural hematoma: a decision analysis. J Neurosurg (2010) 1.33
Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood (2002) 1.30
In vivo imaging of 64Cu-labeled polymer nanoparticles targeted to the lung endothelium. J Nucl Med (2007) 1.30
Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther (2005) 1.29
ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood (2003) 1.28
Traumatic axonal injury results in biphasic calpain activation and retrograde transport impairment in mice. J Cereb Blood Flow Metab (2003) 1.26
LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol (2006) 1.26
Partial interruption of axonal transport due to microtubule breakage accounts for the formation of periodic varicosities after traumatic axonal injury. Exp Neurol (2011) 1.26
Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem (2002) 1.26
Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol (2006) 1.25
Determinants of PF4/heparin immunogenicity. Blood (2007) 1.25
Thalamic nuclei after human blunt head injury. J Neuropathol Exp Neurol (2006) 1.24
Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. Proc Natl Acad Sci U S A (2004) 1.23
Common data elements in radiologic imaging of traumatic brain injury. J Magn Reson Imaging (2010) 1.23
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Brain Res Dev Brain Res (2005) 1.23
Development of transplantable nervous tissue constructs comprised of stretch-grown axons. J Neurosci Methods (2005) 1.23
In-vitro approaches for studying blast-induced traumatic brain injury. J Neurotrauma (2009) 1.23
Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood (2002) 1.21
Coagulopathy in traumatic brain injury. Neurocrit Care (2004) 1.20
Long-term survival and outgrowth of mechanically engineered nervous tissue constructs implanted into spinal cord lesions. Tissue Eng (2006) 1.20
Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J Immunother (2006) 1.19
Long-term accumulation of amyloid-beta in axons following brain trauma without persistent upregulation of amyloid precursor protein genes. J Neuropathol Exp Neurol (2002) 1.18
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. J Cereb Blood Flow Metab (2008) 1.18
Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood (2003) 1.18
Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials (2007) 1.17
Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J (2004) 1.17